• <xmp id="1ykh9"><source id="1ykh9"><mark id="1ykh9"></mark></source></xmp>
      <b id="1ykh9"><small id="1ykh9"></small></b>
    1. <b id="1ykh9"></b>

      1. <button id="1ykh9"></button>
        <video id="1ykh9"></video>
      2. west china medical publishers
        Keyword
        • Title
        • Author
        • Keyword
        • Abstract
        Advance search
        Advance search

        Search

        find Keyword " 生存率" 5 results
        • Clinical Significance of Bilateral Supraclavicular Lymph Node Dissection for Intrathoracic Esophageal Carcinoma

          Abstract: Objective To evaluate the clinical significance of bilateral supraclavicular lymph node dissection after esophagectomy for patients with intrathoracic esophageal carcinoma. Methods A total of 197 patients with esophageal carcinoma but no obvious supraclavicular lymph node metastasis who underwent esophagectomy in Zhongshan Hospital of Xiamen University from March 1997 to September 2004 were included in this study. All the patients were divided into 2 groups, the control group and the study group. In the control group (non-supraclavicular lymphadenectomy group), there were 96 patients including 62 males and 34 females with their age of 40-69 (55.2±3.1) years, who received 2-field lymphadenectomy (intrathoracic lymphatic drainage area and left paracardial lymph nodes) without supraclavicular lymph node dissection. In the study group (supraclavicular lymphadenectomy group), there were 101 patients including 68 males and 33 females with their age of 41-68 (53.8±4.5) years, who received 3-field lymphadenectomy including intrathoracic lymphatic drainage area, left paracardial lymph nodes and bilateral supraclavicular lymph node dissection. Postoperative survival rate, lymph node metastasis rate, anastomotic site recurrence rate, and long-term supraclavicular lymph node metastasis rate were compared between the 2 groups. Results The overall 5-year survival rate of all the patients was 39.59% (78/197). There was no statistical difference in 5-year survival rate between the 2 groups [37.50% (36/96) vs. 41.58%(42/101), P>0.05]. However, the 5-year survival rate of the patients with esophageal carcinoma in the upper third of the esophagus in the study group was significantly higher than that of the control group [38.10%(8/21) vs. 29.17% (7/24), P<0.05]. The intrathoracic lymph node metastasis rate (14.58% vs. 12.87%), abdominal lymph node metastasis rate (6.25% vs. 7.92%)and anastomotic site recurrence rate (5.20% vs. 5.94%)of the control group and study group were not statistically different (P>0.05). However, long-term supraclavicular lymph node metastasis rate of the study group was significantly lower than that of the control group (2.97% vs. 8.33%, P<0.05) Conclusion Bilateral supraclavicular node dissection can significantly increase postoperative survival rate and decrease long-term supraclavicular lymph node metastasis rate of patients with esophageal carcinoma in the upper third of the esophagus.

          Release date:2016-08-30 05:28 Export PDF Favorites Scan
        • Bentall手術治療馬方綜合征的療效分析

          目的 評價Bentall手術治療馬方綜合征(Marfan syndrome)的近、遠期療效。 方法 回顧性分析沈陽軍區總醫院1998年3月至2011年2月連續收治的65例馬方綜合征患者的臨床資料,其中男41例,女24例;年齡8~62(42.1±13.3)歲。合并主動脈夾層動脈瘤De BakeyⅠ型14例,Ⅱ型2例;重度主動脈瓣關閉不全42例,中度二尖瓣關閉不全7例,中度三尖瓣關閉不全4例。行經典法Bentall手術29例,紐扣法Bentall手術36例;同期行其它復雜手術18例。術后隨訪2~163個月, 分析Bentall手術治療馬方綜合征近、遠期療效,同時比較行經典法與紐扣法Bentall手術患者的生存率。 結果 手術時間215~675 (359.0±104.0) min,體外循環時間103~318 (157.0±41.0) min,主動脈阻斷時間60~159 (94.0±25.0) min,深低溫停循環時間13~35 (23.0±7.0) min。術后住重癥監護室時間1~21 (5.4±3.5) d,機械通氣輔助時間1~11 (2.3±2.2) d,住院時間8~59 (28.1±10.6) d。住院死亡4例(6.1%),術后早期并發癥25例(38.5%)。隨訪期間死亡12例(19.7%),遠期并發癥11例(18.0%)。所有痊愈出院患者1年、3年、5年和10年生存率分別為96.5%±2.5%、86.1%±4.9%、77.5%±6.5%和69.7%±7.9%,生存(10.6±0.7)年,95% CI (9.1,12.0)。行紐扣法Bentall手術患者生存率高于經典法Bentall手術,且差異有統計學意義(P=0.034)。 結論 Bentall手術治療馬方綜合征安全、有效,近期及遠期結果滿意,行紐扣法Bentall手術患者生存率更高。

          Release date:2016-08-30 05:28 Export PDF Favorites Scan
        • Clinicopathological Features and Outcomes of Multidisciplinary Therapy of Primary Esophageal Small-cell Carcinoma

          Abstract: Objective To investigate prognosis factors of primary small cell carcinoma of the esophagus (PSCCE), and to optimize the treatment strategy of PSCCE. Method We retrospectively analyzed clinical data of 15 patients (13 males and 2 females with an age of 57.7±2.3 years) with middle thoracic PSCCE in West China Hospital from June 2005 to February 2010. We searched ISI and MEDLINE from April 2001 to February 2010 to extract clinical data of 139 PSCCE patients with 94 males and 45 females with an age of 63.3±10.7 years. We analyzed prognosis factors of the 139 patients including gender, age, tumor location, pathological type, lesions stage and treatment strategy by Kaplan-Meier. Difference in survival curves between limited disease patients and extended disease patients was tested by log-rank test. Results Among the 15 patients, 14 patients had limited disease, and 1 patient had extended disease. Their data were not included in survival analysis because the follow-up was incomplete. Among the 139 patients, 88 patients had limited disease with their 2-year survival rate of 31.8% (28/88). Fifty-one patients had extended disease with their 2-year survival rate of 7.8% (4/51). The 2-year survival rate between limited-disease patients and extended-disease patients was statistically different(P<0.05). Radiation therapy in combination with chemotherapy had significant influence on the survival rate of patients with either local lesions or advanced lesions(P< 0.05), while other factors such as gender, age and tumor location had no significant influence on their survival rate(P>0.05). Conclusion Chemotherapy is the fundamental treatment of PSCCE, which plays an important role in reducing PSCCE preoperative staging and restraining PSCCE postoperative recurrence and metastasis. Surgery and radiation therapy are effective for patients with local lesions. Local treatment in combination with chemotherapy is effective for patients with limited disease. Radiation therapy in combination with chemotherapy is the standard therapy for patients with extended lesions,

          Release date:2016-08-30 05:50 Export PDF Favorites Scan
        • Short- and Long-term Outcomes of 231 Consecutive Patients Undergoing Complete Video-assisted Thoracoscopic Surgery Lobectomy for Non-Small Cell Lung Cancer

          Objective To evaluate the safety,efficacy,short- and long-term clinical outcomes of complete video-assisted thoracoscopic surgery (VATS) lobectomy for non-small cell lung cancer (NSCLC). Methods Clinical data of231 consecutive patients with NSCLC who underwent complete VATS lobectomy in the First Affiliated Hospital of NanjingMedical University between June 2006 and March 2011 were retrospective analyzed. There were 132 male and 99 femalepatients with their age of 15-81 (59.51±11.90) years. Preoperative cancer staging wasⅠa in 149 patients,Ⅰb in 50 patients,Ⅱa in 14 patients,Ⅱb in 13 patients and Ⅲa in 5 patients. There were 152 patients with adenocarcinoma,41 patients with squamous carcinoma,23 patients with bronchioalveolar carcinoma,5 patients with adenosquamous carcinoma,4 patients with large cell carcinoma,and 6 patients with other carcinoma. Follow-up data were statistically analyzed,and short-and long-term survival rates were calculated. Results No perioperative mortality was observed. Operation time was 60-370(199.14±51.04) minutes,and intraoperative blood loss was 10-2 300 (168.19±176.39) ml. Thirty-seven patients had postoperative complications including air leak,pulmonary infection,atelectasis,arrhythmia,subcutaneous emphysema andothers,who were all cured after conservative treatment. Mean number of dissected lymph nodes was 11.14±5.49,and meannumber of explored nodal stations was 3.66±1.52. There were 51 patients (22.08%) whose postoperative cancer staging wasmore advanced than preoperative cancer staging. Postoperative hospital stay was 3-36 (10.79±5.13) days. Primary causesof prolonged postoperative hospitalization included pulmonary air leak,pulmonary infection,preoperative concomitant chronic pulmonary diseases (COPD,asthma),and moderate to severe pulmonary dysfunction. A total of 228 patients werefollowed up for a mean duration of 40.83 months (22-82 months),and 3 patients were lost during follow-up. Overall 5-yearsurvival rates were 85.78%,52.54% and 32.70% for stageⅠ,stageⅡand stageⅢ-Ⅳpatients respectively. Five-year cancerfreesurvival rates were 80.00%,45.37% and 20.99% for stageⅠ,stageⅡand stageⅢ-Ⅳpatients respectively. ConclusionThe advantages of VATS lobectomy include smaller surgical incision,less injury and postoperative pain,quicker postoperative recovery and shorter hospital stay. Long-term survival rate is comparable to previous international and Chinese studies. VATS lobectomy can anatomically achieve complete tumor resection and systematic lymph node dissection. VATS lobectomy will become a standard surgical procedure for NSCLC patients.

          Release date:2016-08-30 05:47 Export PDF Favorites Scan
        • 氟尿嘧啶緩釋顆粒植入食管癌瘤床對食管癌根治術后局部復發的影響

          目的 觀察氟尿嘧啶緩釋顆粒瘤床植入對食管癌根治術后局部復發的療效和預后影響。 方法 納入2009年1~12月期間重慶三峽中心醫院60例行食管癌根治術患者,按其治療方法分為試驗組和對照組兩組,每組30例。試驗組男24例、女6例,年齡(62.00±7.70)歲;對照組男23例、女7例,年齡(60.20±8.20)歲。試驗組患者術中在瘤床植入氟尿嘧啶緩釋顆粒300 mg,對照組不植入任何物質。比較兩組患者臨床結果差異。 結果 兩組患者術后主要并發癥發生率差異無統計學意義(P>0.05),試驗組術后復發時間較對照組顯著延長(P<0.05)、試驗組術后復發病灶大小及復發病灶的個數較對照組顯著減少(P<0.05);兩組患者1年生存率差異無統計學意義,但試驗組患者2年及3年生存率顯著高于對照組(P<0.05),試驗組中位生存時間較對照組顯著延長[(29.2±1.9)月 vs. (23.4±1.4)月,P<0.05] 。 結論 食管癌術中瘤床植入氟尿嘧啶緩釋顆粒能延緩腫瘤復發時間、提高食管癌患者2年及3年生存率,延長患者中位生存時間,而不增加術后并發癥的發生,是一種安全、有效的局部化療方法。

          Release date:2016-08-30 05:47 Export PDF Favorites Scan
        1 pages Previous 1 Next

        Format

        Content

      3. <xmp id="1ykh9"><source id="1ykh9"><mark id="1ykh9"></mark></source></xmp>
          <b id="1ykh9"><small id="1ykh9"></small></b>
        1. <b id="1ykh9"></b>

          1. <button id="1ykh9"></button>
            <video id="1ykh9"></video>
          2. 射丝袜